bims-glucam Biomed News
on Glutamine cancer metabolism
Issue of 2026–11–15
twenty-six papers selected by
Sreeparna Banerjee, Middle East Technical University



  1. Cell Commun Signal. 2026 Aug 13. pii: 603. [Epub ahead of print]24(1):
       BACKGROUND: Triple-negative breast cancer (TNBC) exhibits early metastasis, a unique metabolic rigidity and poor clinical outcomes. A substantial, biomarker-definable subset of TNBC depends on glutamine metabolism, which can act as a nutrient source and a regulator of proliferation, redox homeostasis, epigenetic remodelling, and immune evasion.
    MAIN BODY: Glutamine metabolism in TNBC involves several interrelated processes, including transporter regulation, transcriptional control (FOXM1/FUS/SLC7A5 axis), and organelle-specific redox adaptation (ER-PPP/H6PD pathway). Various transporters mediate the uptake of glutamine into the cells. Once inside the cells, glutamine undergoes enzymatic conversion, driving essential metabolic pathways that support the tumor's energy needs, maintain cellular redox balance, and drive epigenetic changes that promote cancer progression. Furthermore, the tumor microenvironment, including spatial immune-metabolic competition/heterogeneity, is significantly influenced by glutamine metabolism. The availability of glutamine can regulate the behavior of immune cells, including T cells and macrophages, potentially leading to immune suppression and contributing to therapeutic resistance.
    CONCLUSION: We concluded that glutamine metabolism is a key dependency in a substantial, biomarker-definable subset of TNBC. The therapeutic potential of glutamine metabolism not only offers a promising avenue for improving treatment outcomes but also presents a means to overcome current therapeutic limitations in TNBC.
    Keywords:  Amino acid transporters; Glutamine metabolism; TNBC; Tumor microenvironment; mTORC1 signaling
    DOI:  https://doi.org/10.1186/s12964-026-03150-1
  2. Cell Signal. 2026 Nov 11. pii: S0898-6568(26)00659-5. [Epub ahead of print] 112999
      Osteoarthritis (OA) is the most prevalent joint disease worldwide, characterized by progressive cartilage degeneration and chondrocyte apoptosis, yet effective disease-modifying therapies are lacking. Mitochondrial dysfunction is an important factor contributing to OA pathogenesis. Since mitochondrial homeostasis relies on an adequate supply of metabolic substrates, metabolic disturbances may further impair mitochondrial function. In this context, glutamine is essential for maintaining electron transport chain integrity. However, the contribution of glutamine to OA pathogenesis remains poorly characterized. Here, reanalysis of a publicly available transcriptomic dataset from a rat OA model identified significant downregulation of the glutamine transporter SLC38A3. Reduced SLC38A3 expression decreased intracellular glutamine levels, which subsequently suppressed the AMPK/PINK1/Parkin mitophagy pathway and promoted chondrocyte apoptosis. These effects were rescued by glutamine supplementation in an SLC38A3-dependent manner, whereas direct AMPK activation could restore mitophagy independent of SLC38A3. Our findings suggest SLC38A3 as a potential regulatory node linking glutamine availability to mitochondrial quality control in chondrocytes.
    Keywords:  AMPK; Glutamine; Mitochondrial homeostasis; Mitophagy; Osteoarthritis; SLC38A3
    DOI:  https://doi.org/10.1016/j.cellsig.2026.112999
  3. Hypertension. 2026 Nov 10.
       BACKGROUND: The transcriptional mechanisms governing macrophage glutamine metabolism in pulmonary arterial hypertension remain incompletely understood. We investigated the role of ZEB1 (zinc finger E-box-binding homeobox 1)-mediated transcriptional regulation in macrophage metabolic reprogramming and the development of pulmonary arterial hypertension.
    METHODS: Clinical samples and multiomics data sets were analyzed to characterize ZEB1 expression in pulmonary arterial hypertension. Myeloid-specific ZEB1 conditional knockout mice were subjected to hypoxia-induced pulmonary hypertension. Transcriptomic sequencing, metabolomic profiling, chromatin immunoprecipitation-quantitative polymerase chain reaction, dual-luciferase reporter assays, and coimmunoprecipitation were integrated to define ZEB1-dependent molecular, metabolic, and inflammatory programs in pulmonary and bone marrow-derived macrophages. Therapeutic potential was further evaluated using pharmacological interventions and adenoviral ZEB1 silencing in monocrotaline-induced pulmonary hypertension in rats.
    RESULTS: ZEB1 was upregulated in pulmonary arterial hypertension and enriched in recruited disease-associated macrophages. Myeloid-specific ZEB1 deletion attenuated macrophage inflammation, pulmonary vascular remodeling, and right ventricular dysfunction. Mechanistically, ZEB1 bound the GLS (glutaminase) promoter and recruited BRD4 (bromodomain-containing protein 4), enhancing histone H3 lysine 27 acetylation at the GLS promoter and promoting GLS transcription and glutamine metabolic reprogramming. Restoration of GLS partially reversed the metabolic and inflammatory effects of ZEB1 deficiency. Pharmacological targeting of ZEB1, combined BRD4 and GLS inhibition, and adenoviral ZEB1 silencing ameliorated experimental pulmonary hypertension.
    CONCLUSIONS: ZEB1 promotes macrophage glutamine metabolic reprogramming by recruiting BRD4 and enhancing histone H3 lysine 27 acetylation-dependent GLS transcription. This ZEB1-driven metabolic program promotes macrophage inflammation and pulmonary vascular remodeling, identifying the ZEB1-BRD4-GLS regulatory axis as a potential therapeutic target in pulmonary arterial hypertension.
    Keywords:  H3K27ac modification; ZEB1; glutamine metabolism; inflammation; transcriptional regulation
    DOI:  https://doi.org/10.1161/HYPERTENSIONAHA.126.27213
  4. bioRxiv. 2026 Oct 21. pii: 2026.10.20.760504. [Epub ahead of print]
      Histone monoaminylation, including serotonylation, dopaminylation, and histaminylation, is an emerging class of epigenetic modifications that regulates gene transcription in diverse physiological and disease contexts. Histone H3 glutamine 5 (H3Q5) was the first identified and remains a major site of monoaminylation on core histones. Mechanistically, monoaminylation involves the formation of an isopeptide bond between a substrate glutamine and a monoamine metabolite through a reversible transamidation reaction catalyzed by transglutaminases (TGs). Among the nine members of the human TG family, TG2 has been established as the major writer of H3Q5 monoaminylation. Here, we identify TG3 as an additional histone monoaminylation writer capable of catalyzing H3Q5 histaminylation (H3Q5his).
    DOI:  https://doi.org/10.64898/2026.10.20.760504
  5. Diagnostics (Basel). 2026 Nov 04. pii: 3639. [Epub ahead of print]16(21):
      Background: Cervical cancer is accompanied by metabolic reprogramming, but circulating NMR metabolite signatures require rigorous statistical assessment before clinical interpretation. Methods: Serum metabolite concentrations were analyzed in 33 cervical cancer (CC) cases and 31 normal controls (NC). Group differences across 35 primary metabolites were assessed using Welch's t-test with Benjamini-Hochberg false-discovery-rate (FDR) control; Mann-Whitney tests were used as distribution-robust sensitivity analyses. Age-adjusted linear models with HC3 robust standard errors were fitted for each primary metabolite (primary analysis: raw concentrations; sensitivity analysis: log2-transformed concentrations), with FDR correction across the 35 models. MQ was defined as [glutamine] + [myo-inositol]. ROC discrimination was summarized using stratified-bootstrap 95% confidence intervals, and paired DeLong testing compared MQ with glutamine. Results: Glutamine (CC 229.7 ± 102.2 μM; NC 434.8 ± 123.8 μM) and myo-inositol (CC 18.3 ± 8.8 μM; NC 35.8 ± 11.0 μM) were lower in CC, and both remained significant after age adjustment and FDR correction. Within CC, serum glutamine was strongly inversely correlated with tumor length (Spearman ρ = -0.94, n = 31; exploratory, requires independent replication). Apparent ROC AUCs were 0.906 for glutamine, 0.889 for myo-inositol, and 0.919 for MQ. The paired DeLong comparison of MQ versus glutamine was not statistically significant (AUC difference 0.0132; approximate 95% CI -0.0031 to 0.0295; p = 0.113). Repeated cross-validation is reported as within-cohort resampling performance and not independent validation. Conclusions: The findings support lower circulating glutamine and myo-inositol in this cohort. MQ is an exploratory additive feature without demonstrated superiority over glutamine alone; external validation and adjustment for additional clinical confounders are required.
    Keywords:  MQ; NMR-based metabolomics; age-adjusted analysis; cervical cancer; exploratory discrimination; glutamine; myo-inositol
    DOI:  https://doi.org/10.3390/diagnostics16213639
  6. Cancer Res. 2026 Nov 12.
      Many tumors remain poorly responsive to immune checkpoint blockade. The metabolic microenvironment in tumors can mediate immunosuppression by failing to sustain productive cytotoxic lymphocyte function. Here, we showed that a coordinated ketogenic-fasting (KF) regimen sensitized immune-refractory tumors to PD-1 blockade by integrating distinct metabolic and microbial effects of ketogenic diet (KD) and intermittent fasting (IF). The KF combination established a distinct immunometabolic state that could not be fully recapitulated by either KD or IF intervention alone. KF induced systemic glucose restriction while preserving intratumoral glutamine availability and selectively upregulating the glutamine transporters SLC38A1 and SLC38A2 in tumor-infiltrating CD8+ T cells and NK cells, fueling interferon-STAT1 signaling and effector activity. Single-cell transcriptomic analysis identified KF-associated cytotoxic lymphocyte states characterized by enhanced nutrient access signatures, increased effector function, and reduced terminal dysfunction. Microbiota depletion attenuated KF-mediated tumor control without abolishing intratumoral glutamine enrichment. Fecal microbiota transfer and monocolonization identified Odoribacter splanchnicus as sufficient to restore tumor control and cytotoxic T-cell activity in microbiota-depleted hosts. Mechanistically, O. splanchnicus was linked to host polyamine remodeling and indole-3-lactic acid, which supported durable CD8+ T-cell functions distinct from the glutamine-driven effector arm. KF enhanced anti-PD-1 efficacy in immune-cold tumor models, and public human datasets showed concordant associations between glutamine context, Odoribacter abundance, and immunotherapy response. Together, these findings identify a diet-responsive host-microbiota metabolic mechanism that stimulates antitumor immunity and sensitizes immune-cold tumors to immunotherapy.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-1941
  7. Mol Cell. 2026 Nov 12. pii: S1097-2765(26)00742-2. [Epub ahead of print]
      Perturbed glucose homeostasis is a hallmark of metabolic disease and cancer, and cellular responses to excess glucose are tightly controlled. We report here a lysosomal glucose sensing axis linking the transporter GLUT1 with the lysosomal protein DRAM1. Pathophysiological glucose induces DRAM1 via the MLX/ChREBP transcriptional complex. DRAM1 then binds newly synthesized GLUT1 and promotes its traffic to lysosomes without degradation, reducing surface GLUT1 and acting as a reversible brake on glucose entry. Hexokinase or glucose-6-phosphate (G6P) dehydrogenase disruption weakens DRAM1-GLUT1 complex formation, whereas nicotinamide adenine dinucleotide phosphate(NADPH) oxidase (NOX) inhibition enhances assembly, implicating NADPH as a key metabolic signal downstream of elevated glucose. Sequestration of GLUT1 suppresses glucose uptake and glycolysis and rewires metabolism toward glutamine anaplerosis, creating vulnerability to glutaminase (GLS) inhibition. In vivo, Dram1-/- tumors display a glycolytic metabolite profile, consistent with loss of this brake. Together, these data define an mTORC1- and AMPK-independent lysosomal mechanism that protects metabolic homeostasis under hyperglycemic conditions.
    Keywords:  DRAM1; GLUT1; NADPH; glucose sensing; glutamine anaplerosis; hyperglycemia; lysosomes; metabolism
    DOI:  https://doi.org/10.1016/j.molcel.2026.10.022
  8. Cancer Cell Int. 2026 Aug 17. pii: 360. [Epub ahead of print]26(1):
       BACKGROUND: Metabolic reprogramming is a hallmark of breast cancer (BrCa), with alterations in glycolysis, glutamine metabolism, and the urea cycle contributing to tumour progression. Dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, shifts metabolism toward oxidative phosphorylation and has been proposed as a therapeutic agent. While isotope tracing is well-established, natural isotope abundance (δ¹³C, δ¹⁵N) is emerging as a biomarker of metabolic alterations in cancer.
    METHODS: We investigated the relationship between isotope composition and metabolism in BrCa using two BALB/c mouse mammary tumour models (V14 and 4T1) and assessed the effects of DCA treatment using metabolomics, lipidomics and isotopomics.
    RESULTS: V14 and 4T1 tumours exhibited isotopic patterns similar to human tumours, with δ¹³C enrichment and δ¹⁵N depletion relative to non-cancerous mammary tissue. V14 tumours were more δ¹⁵N-depleted than 4T1, reflecting differences in nitrogen metabolism. Multivariate analysis integrating isotopic, metabolomic, and lipidomic data revealed isotopic features as key discriminators between tumours and normal tissues. Compared to V14, 4T1 tumours were enriched in TCA intermediates, sphingolipids, and amino acids, whereas V14 tumours showed elevated glutaminolytic and nitrogenous metabolites. DCA treatment differentially affected tumour growth, with V14 tumours more sensitive than 4T1. DCA altered nitrogen metabolism, increasing the arginine-to-ornithine ratio, and modulating δ¹⁵N values in a tumour-specific manner increasing V14 and decreasing 4T1 δ¹⁵N values. DCA had little effect on δ¹³C. δ¹³C values were primarily determined by the balance between lipid and TCA cycle metabolites, rather than glycolytic flux. δ¹⁵N variation was linked to nitrogen metabolism, including urea cycle intermediates and sphingolipid composition, with a potential role for choline-related fractionation in δ¹⁵N depletion. Altered gene expression of Hacd2 and Acot12 in V14 tumours after DCA treatment was reflected in shorter fatty acid tails in phosphatidyl cholines, supporting the lipidomics data.
    CONCLUSIONS: These findings support the hypothesis that cancer-associated metabolic reprogramming influences natural isotope abundance. Correlations between isotope shifts and metabolic signatures highlight the potential of lipid-derived δ¹⁵N as a biomarker of tumour metabolic state, with implications for noninvasive metabolic profiling in BrCa.
    Keywords:  Breast cancer; Dichloroacetate; Lipidomics; Mammary tumour; Metabolomics; Natural isotope abundance
    DOI:  https://doi.org/10.1186/s12935-026-04446-5
  9. Molecules. 2026 Oct 22. pii: 3791. [Epub ahead of print]31(21):
      Metabolic plasticity limits mitochondria-directed cancer therapy by enabling glycolytic compensation during respiratory stress. Our previous nano-energy interference (NEI) platform showed that coupling azelaic acid (AZA)-induced mitochondrial disruption with restriction of glucose utilization suppresses colorectal cancer (CRC), but the upstream program coordinating this adaptive response remained unresolved. Here, we identify HIF-1α-dependent glycolytic adaptation as a key response to AZA-induced respiratory inhibition and develop glutamine-functionalized lipid nanoparticles (G-LNPs) to deliver dominant-negative HIF-1α (dnHIF-1α) mRNA. G-LNPs were approximately 105 nm in diameter, achieved >90% mRNA encapsulation, and enhanced uptake and functional reporter mRNA expression in ASCT2-expressing MC38 cells in a GPNA-sensitive manner. AZA suppressed mitochondrial respiration while activating HIF-responsive transcription, glycolytic activity, lactate production, and GLUT1, HK2, LDHA, and PDK1 expressions. G-LNP-delivered dnHIF-1α blocked this compensatory response without materially intensifying respiratory inhibition, thereby deepening ATP depletion and producing a distinct treatment-associated metabolomic state. Following treatment withdrawal and equal viable cell replating, the combination caused persistent impairment of regrowth and clonogenic capacity. In subcutaneous MC38 tumors, combined treatment produced the greatest tumor growth inhibition without overt systemic toxicity. Together, these findings support transient disruption of HIF-dependent metabolic adaptation as a strategy to convert partially recoverable mitochondrial stress into a durable loss of CRC cell fitness.
    Keywords:  HIF-1α; azelaic acid; colorectal cancer; lipid nanoparticles; mRNA delivery; metabolic plasticity
    DOI:  https://doi.org/10.3390/molecules31213791
  10. Transl Cancer Res. 2026 Oct 30. 15(10): 729
       Background: Serum metabolic features associated with microvascular invasion (MVI) and recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remain unclear. We examined MVI-associated serum metabolic changes and the association of a glutaminolysis index with post-transplant recurrence.
    Methods: We analysed pre-transplant serum from 151 HCC recipients undergoing LT, including 61 MVI-positive and 90 MVI-negative recipients, using a targeted panel of 209 metabolites. The index was calculated as z(glutamate) - z(glutamine) + z(alpha-ketoglutarate) and evaluated by receiver operating characteristic (ROC), Kaplan-Meier, and Cox analyses.
    Results: MVI-positive recipients had a higher recurrence rate and shorter median recurrence-free survival (RFS) than MVI-negative recipients (47.5% vs. 21.1%, P<0.001; 18.5 vs. 51.2 months, P<0.001), with lower glutamine and higher glutamate and alpha-ketoglutarate levels. The index had an area under the curve (AUC) of 0.695 [95% confidence interval (CI): 0.604-0.781; Youden cutoff, 0.555] and was associated with recurrence after adjustment for age, sex, alpha-fetoprotein (AFP), MVI, and Milan status [hazard ratio (HR) =1.36, 95% CI: 1.02-1.80, P=0.04]. In MVI-positive recipients, the index was associated with recurrence (HR =1.75, P=0.002), with recurrence in 24% of low-index and 64% of high-index recipients. In MVI-negative recipients, recurrence was mainly associated with a purine/energy-charge metabolic pattern.
    Conclusions: MVI-positive recipients showed a serum glutaminolysis profile before LT. The glutaminolysis index may be a biomarker for recurrence after LT, particularly in MVI-positive recipients. The purine/energy-charge pattern in MVI-negative recipients requires further validation.
    Keywords:  Hepatocellular carcinoma (HCC); glutaminolysis; liver transplantation (LT); microvascular invasion (MVI); serum metabolomics
    DOI:  https://doi.org/10.21037/tcr-2026-2254
  11. bioRxiv. 2026 Oct 20. pii: 2026.10.06.757091. [Epub ahead of print]
      Drosophila melanogaster is a powerful model for studying systemic metabolism. Although metabolism is compartmentalized across tissues, prior work in adult Drosophila has mostly measured it in dissected tissues rather than in situ , limiting the spatial information that can be gained. Here, we combine whole-fly massspectrometry imaging with stable-isotope tracing and flux modeling to quantify metabolic activities across the adult fruit fly in a spatially resolved manner. Across 68 tracer-fed Oregon-R female flies and 187,709 pixels, we map 81 metabolites onto eight annotated regions, including muscle, fat body, gut, and nervous system. Glucose labeling and fitted relative fluxes indicate higher glycolytic and tricarboxylic acid cycle turnover in thoracic muscle than in abdominal fat body; proline labels the nervous system and eye; glutamine the abdominal reproductive system and gut. Alanine carries glucose-derived carbon through the hemolymph and transfers nitrogen into glutamate. In flies bearing yorkie-driven gut tumors, alanine contribution to malate rises in gut and abdomen, and reducing gut alanine uptake lowers tumor burden. Together, this work establishes a framework for quantitative spatial metabolic analysis, showing compartmentalized nutrient use across the adult fruit fly.
    DOI:  https://doi.org/10.64898/2026.10.06.757091
  12. Ecotoxicol Environ Saf. 2026 Nov 12. pii: S0147-6513(26)01376-X. [Epub ahead of print]327 121046
      Lead (Pb) is one of the oldest recognized environmental neurotoxicants with its toxic potential especially pronounced in early-life stages, where even very low exposures can result in long-lasting adverse effects. The glutamatergic system important for cognitive function and closely associated with memory impairment and various neurological disorders is one target of Pb. In this study, glutamatergic mechanisms underlying low-concentration Pb exposure during neurodevelopment were evaluated in F0 and F1 generation of zebrafish. For the F0, wild-type embryos (5D strain) were exposed to 0, 0.01, 0.1, or 1 part per billion (ppb, µg/L) Pb from 1 to 72 h post fertilization (hpf). Following exposure, fish were rinsed and either grown to 120 hpf for neurological assessments or raised to 4 months and bred to generate the F1 (exposed as germ cells). Levels of glutamate, glutamine, glutathione, and NMDAR were measured. Biochemical activity of enzymes involved in glutamatergic metabolism were also evaluated alongside targeted lipidomic profiling. Non-associative learning was assessed using the acoustic startle response (ASR) test. Data suggest Pb developmental neurotoxicity is driven by a combination of glutamate accumulation and upregulation of NMDAR, which coupled contribute to excitotoxicity and impaired learning. These impacts were most significant in the group exposed to 1 ppb in the F0 generation. The findings of this study demonstrate Pb exerts its neurotoxic effects through multi-target mechanisms involving metabolic, enzymatic, and lipid-mediated disruption of the glutamatergic pathway with these effects being restricted to the embryonic exposed generation with limited evidence of multigenerational transmission.
    Keywords:  Acoustic startle response; Glutamate synthesis; Glutamine; Glutathione; Lipid dysfunction
    DOI:  https://doi.org/10.1016/j.ecoenv.2026.121046
  13. Dev Cell. 2026 Nov 11. pii: S1534-5807(26)00395-3. [Epub ahead of print]61(11): 2193-2212.e8
      p53 protects against the initiation and progression of cancers, but the mechanisms underlying this function remain incompletely understood. Chaperone-mediated autophagy (CMA) is a form of autophagy unique in vertebrates, yet its regulation and function are unclear. Here, we demonstrate that p53 functions as a central activator of CMA, integrating stress signals to regulate this selective autophagic pathway. Mechanistically, the energy sensor AMP-activated protein kinase (AMPK) inhibits CMA by preventing oligomerization of its receptor LAMP2A. Cytoplasmic p53 interacts with AMPK and relieves this inhibition. By activating CMA, p53 promotes lysosomal degradation of isocitrate dehydrogenases IDH1 and IDH2, thereby reducing intracellular α-ketoglutarate levels, inhibiting reductive glutamine metabolism, and suppressing growth of lung and liver cancers. Tumor-associated p53 mutants fail to promote CMA, whereas oncogenic IDH1/2 mutants evade CMA-mediated degradation. These results suggest that CMA activation may be a fundamental component of p53 function, through which it modulates metabolism and inhibits oncogenic growth.
    Keywords:  AMPK; CMA; IDH1; IDH2; LAMP2A; autophagy; chaperone-mediated autophagy; p53; reductive carboxylation; α-ketoglutarate
    DOI:  https://doi.org/10.1016/j.devcel.2026.10.009
  14. Cancers (Basel). 2026 Nov 08. pii: 3586. [Epub ahead of print]18(21):
      Hepatocellular carcinoma (HCC) usually arises within chronically injured liver tissue, where inflammation, fibrosis, metabolic dysfunction, and immune remodeling shape tumor evolution and therapeutic response. This biological complexity has increased interest in regulators capable of connecting tumor-intrinsic programs with the diseased hepatic microenvironment. SET and MYND domain-containing protein 2 (SMYD2) is a lysine methyltransferase that modifies histone and non-histone substrates involved in transcriptional control, tumor suppressor regulation, DNA damage repair, metabolism, cellular plasticity, and inflammatory signaling. In HCC, increased SMYD2 expression has been associated with aggressive clinicopathological features and poor outcome, while functional studies link SMYD2 to tumor cell proliferation, c-Myc/GLS1-dependent glutamine metabolism, stemness-associated programs, sorafenib resistance, and immune evasion. Mechanistically, SMYD2 may act through multiple context-dependent pathways, including β-catenin methylation, BMP4/SMAD/ID3 signaling, TLR4/NF-κB-dependent hepatic stellate cell activation, and Wnt ligand-mediated tumor-macrophage communication, leading to TGF-β-associated immune suppression. In preclinical HCC models, SMYD2 inhibition has reduced tumor growth and enhanced responses to sorafenib or anti-PD-1 treatment, although its clinical efficacy and safety remain to be established. This translational uncertainty is particularly relevant because SMYD2 dependency is not uniform across cancer models, and its functions in non-tumoral liver, macrophages, and acute hepatic injury suggest that systemic inhibition may have compartment- and context-specific consequences. This review summarizes the structural basis, biological functions, and therapeutic implications of SMYD2 in HCC, emphasizing both its mechanistic relevance and the questions that will need to be resolved before clinical translation.
    Keywords:  SMYD2; SMYD2 inhibition; hepatocellular carcinoma; immune evasion; lysine methyltransferase; metabolic reprogramming; tumor microenvironment
    DOI:  https://doi.org/10.3390/cancers18213586
  15. Sci Adv. 2026 Nov 13. 12(46): eaej2663
      PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1-targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.
    DOI:  https://doi.org/10.1126/sciadv.aej2663
  16. Front Immunol. 2026 ;17 1962178
      Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, with the EWSR1-FLI1 fusion gene serving as its core driver event. Although multi-agent chemotherapy has achieved nearly 70% five-year survival in patients with localized disease, the prognosis for those with metastatic or relapsed/refractory disease remains poor, with long-term survival rates below 30%, and no substantial breakthrough has been made in first-line regimens over the past decade. Immune checkpoint inhibitors have revolutionized the treatment landscape for various adult solid tumors, but their efficacy in Ewing sarcoma-a typical "cold" tumor-is limited, owing to its low tumor mutational burden, sparse neoantigens, and highly immunosuppressive microenvironment. Recent studies suggest that EWSR1-FLI1 not only reshapes transcriptional programs but also functions as a metabolic "master switch, " driving enhanced glycolysis, altered glutamine and tryptophan metabolism, and lipid metabolic remodeling. These metabolic alterations, in turn, produce lactate, kynurenine, lipid mediators, and local hypoxia, which suppress effector T cells and natural killer cells, induce regulatory T cells, and polarize macrophages toward a protumor phenotype, thereby forming a self-reinforcing causal chain between metabolism and immunity. This review systematically delineates this chain-from fusion-driven metabolic reprogramming, through metabolism-mediated immunosuppressive mechanisms, to intervention strategies targeting the metabolism-immunity interface. We focus on glycolysis inhibition, blockade of the tryptophan-AHR axis, lipid metabolism interventions, as well as novel surface targets (B7-H3, STEAP1, ENPP1, IL1RAP, MIF-CD74) for cell-based therapies and combination strategies of metabolic modulation with immunotherapy. We further analyze the practical obstacles to translating these strategies into clinical practice and, based on a critical synthesis of available evidence, Propose a metabolic-immune coupling model anchored on the active state of EWS-FLI1 to explain plasticity-driven resistance. This model provides a translational roadmap grounded in metabolic subtyping with the goal of "converting cold tumors to hot, " offering a new framework for improving outcomes in Ewing sarcoma.
    Keywords:  EWSR1−FLI1; Ewing sarcoma; immunometabolism; immunotherapy; lactate; metabolic reprogramming; tryptophan–AhR axis; tumor immune microenvironment
    DOI:  https://doi.org/10.3389/fimmu.2026.1962178
  17. Cells. 2026 Oct 28. pii: 1959. [Epub ahead of print]15(21):
      Metabolic reprogramming is a well-established hallmark of cancer, contributing to adverse behaviors like invasion, metastasis and recruitment of tissue-resident cells to the tumor microenvironment. Among recruitment capabilities, innervation has emerged as an active contributor of disease progression. Despite association with poor patient prognosis, mechanisms governing nerve recruitment at various stages of progression remain poorly understood. This study investigates how different stages of breast cancer cells are associated with the metabolic link of cancer and their pro-axonogenic capability. Here, we used human isogenic MCF10 mammary epithelial cell line series, three-dimensional collagen hydrogels, human adipose stromal cells (ASCs) and freshly isolated rat sensory neurons. Multiphoton optical redox imaging coupled with ATP production rate assays validated direct metabolic inhibition and highlighted the utilization of glutamine in progressed cells. We identified the expressions of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) from pre-malignant and malignant cultures, respectively. Interestingly, when treated with metabolic inhibitors, monocultures of MCF10 cells reduced neurotrophin release while cocultures with ASCs showed no or even elevated neurotrophin secretion. Together, these findings raise the possibility that breast tumor innervation is shaped in part by stage-specific metabolic-neurotrophic coupling, presenting a concrete mechanistic question for future investigation.
    Keywords:  breast cancer; metabolic-neurotrophic coupling; metabolism; neurotrophin; tissue engineering; tumor innervation; tumor microenvironment
    DOI:  https://doi.org/10.3390/cells15211959
  18. Curr Cancer Drug Targets. 2026 Nov 12.
      Following publication of the article entitled "Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Cur-rent Insights and Future Directions" [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminology. To ensure the accuracy and clarity of the published record, these expressions have been corrected using appropriate terminology that more accurately conveys the intended scientific meaning. These corrections are limited to the wording and terminology of the affected passages and do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: Section, Abstract, Original text: However, some studies have shown that inhibitors of this pathway can sensitize PC cells to chemotherapeutic agents, and this synergistic effect provides new insights into the combination therapy for PC. Corrected text: However, some studies have shown that inhibitors of this pathway can sensitize PC cells to chemotherapeutic agents, and this synergistic effect provides new opportunities for developing combination therapies for PC treatment. The original article has been updated accordingly. This corrigendum is published to maintain transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/146023 The authors regret these errors and apologise for any inconvenience they may have caused.
    DOI:  https://doi.org/10.2174/1568009627999261112115235
  19. Crit Rev Oncol Hematol. 2026 Nov 09. pii: S1040-8428(26)00583-4. [Epub ahead of print]228 105696
      Despite significant advances in localized treatment modalities, metastasis remains the primary determinant of mortality in urological malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma. This review synthesizes recent mechanistic insights to provide a conceptual framework of the TAM-driven metastatic cascade. We organize the available evidence into four conceptual phases: the Education phase, where chemokine networks (CCL2/CCR2) and metabolic symbiosis (involving lactate, iron, and glutamine) recruit and reprogram monocytes toward tumor-supportive macrophage states; the Departure phase, where TAMs contribute to epithelial-mesenchymal transition (EMT) and other invasive programs, remodel the extracellular matrix, and induce vasculogenic mimicry to facilitate invasion; the Transit phase, featuring the association of circulating cancer-associated macrophage-like cells (CAMLs) with circulating tumor-cell survival and metastatic progression, potentially through protection from shear stress and immune surveillance; and the Arrival phase, where TAMs contribute to pre-metastatic niche formation and immune suppression through complement- and checkpoint-associated mechanisms through immune checkpoints such as VISTA.
    Keywords:  Immunotherapy; Metabolic Reprogramming; Metastatic Cascade; Tumor Microenvironment; Tumor-Associated Macrophages
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105696
  20. Immunology. 2026 Nov 11.
      Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality worldwide, with its progression and therapeutic resistance increasingly recognized as consequences of complex metabolic and immune interactions within the tumour microenvironment (TME). Recent advances in single-cell and spatial multi-omics technologies have enabled detailed characterisation of metabolic heterogeneity among TME components, uncovering how distinct metabolic states influence immune function and therapeutic responses. In this review, we summarize recent advances in our understanding of metabolic regulation in the CRC microenvironment, with a particular focus on how distinct immune cell populations contribute to tumour progression and immune suppression through diverse metabolic pathways. We discuss key metabolite-driven signalling networks involving lactate, short-chain fatty acids, bile acids, and amino acid derivatives, and examine how these pathways influence immune cell function and tumour-immune interactions. Furthermore, we highlight emerging therapeutic approaches targeting the metabolic-immune axis, including glutaminase inhibitors, CD36 antagonists, and combination regimens integrating metabolic intervention with immune checkpoint inhibitors. By integrating recent mechanistic discoveries with therapeutic perspectives, this review provides an updated overview of the metabolic-immune landscape in CRC and discusses potential strategies to exploit metabolic vulnerabilities for improving immunotherapy efficacy and overcoming treatment resistance.
    Keywords:  colorectal cancer; immunometabolism; metabolic reprogramming; tumour microenvironment
    DOI:  https://doi.org/10.1111/imm.70230
  21. Int J Mol Sci. 2026 Oct 27. pii: 9598. [Epub ahead of print]27(21):
      Hyperinsulinemia is increasingly recognized as a systemic factor that can promote tumor progression by amplifying insulin receptor and insulin-like growth factor (IGF) signaling, reshaping cancer-cell metabolism, and influencing the tumor microenvironment. Commonly associated with obesity, type 2 diabetes, and metabolic syndrome, persistent hyperinsulinemia can enhance insulin/IGF receptor signaling and downstream PI3K-AKT-mTOR and RAS-MAPK pathways. These pathways interact with stress-response networks, including NRF2-dependent redox control and AMPK-autophagy signaling, thereby supporting metabolic plasticity under nutrient and microenvironmental stress. Hyperinsulinemia-associated signaling may increase glucose utilization, pentose phosphate pathway activity, glutaminolysis, de novo lipogenesis, and antioxidant capacity, collectively promoting anabolic growth, survival, and treatment adaptation. Metabolic remodeling extends beyond aerobic glycolysis and involves context-dependent alterations in mitochondrial function, oxidative metabolism, lactate production, and metabolic crosstalk among cancer, stromal, and immune cells. Consequently, hyperinsulinemia-associated signaling may contribute to lactate-rich, immunosuppressive tumor microenvironments, tumor progression, and heterogeneous therapeutic responses across cancer types. This review integrates experimental, epidemiological, and translational evidence linking persistent hyperinsulinemia and insulin/IGF signaling with cancer metabolic reprogramming. It critically examines strategies to reduce systemic insulin exposure, inhibit insulin/IGF signaling, or co-target tumor-specific metabolic dependencies, including the metabolic consequences of PI3K-pathway inhibition. By advancing a hyperinsulinemia-centered framework, this review identifies mechanistic gaps and translational priorities for more precise metabolic interventions in cancer.
    Keywords:  PI3K–AKT–mTOR signaling; hyperinsulinemia; insulin/IGF signaling; metabolic plasticity; metabolic reprogramming; tumor microenvironment
    DOI:  https://doi.org/10.3390/ijms27219598
  22. Molecules. 2026 Nov 03. pii: 3970. [Epub ahead of print]31(21):
      Cancer cells exhibit metabolic reprogramming, including increased aerobic glycolysis, glutaminolysis, and altered lipid metabolism, which supports tumor growth and contributes to immune evasion. A growing but heterogeneous body of literature has investigated whether targeting these metabolic dependencies alongside standard oncologic treatment may provide therapeutic benefit. This review critically examines clinically investigated metabolically directed approaches, including metronomic chemotherapy, hyperthermia, high-dose intravenous vitamin C, hyperbaric oxygen therapy, fasting-related nutritional strategies, ketogenic diets, and insulin-based approaches, while distinguishing them from established targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors. Emerging immunometabolic and microenvironmental targets are also discussed, including lactate transport, ferroptosis, autophagy and amino acid metabolism, cancer-associated fibroblasts, tumor-associated macrophages, abnormal vasculature, and immunosuppressive cytokine signaling. In addition, drug-delivery strategies are considered by distinguishing the established pharmaceutical role of dimethyl sulfoxide (DMSO) as a solvent or excipient from nanoparticle-, exosome-, and peptide-based targeting platforms. Available evidence is characterized according to clinical maturity, ranging from established phase III-supported therapies and randomized clinical evidence to early-phase, preclinical, or currently unproven approaches. Although several metabolically directed interventions have biological rationale and varying degrees of clinical support, no comprehensive multicomponent metabolic regimen has been validated in controlled clinical trials. Future development should prioritize stepwise, biomarker-informed prospective studies evaluating individual interventions and biologically justified combinations alongside standard-of-care therapy. Metabolically directed strategies should therefore be interpreted according to the evidence supporting each component rather than as a single established therapeutic regimen.
    Keywords:  cancer metabolism; evidence-based oncology; metabolic reprogramming; targeted drug delivery; tumor microenvironment
    DOI:  https://doi.org/10.3390/molecules31213970
  23. Adipocyte. 2026 Dec;15(1): 2751414
      Obesity is characterized by the expansion of metabolically dysfunctional visceral adipose tissue (VAT) and chronic low-grade inflammation, which contribute to the development of insulin resistance. However, to what extent VAT bioenergetics and substrate preferences differ across distinct obesity-related glycaemic status profiles remains poorly understood. The present study aimed to assess substrate utilization and metabolic flexibility of VAT from individuals with obesity across different glycaemic statuses, namely euglycemia, prediabetes, and type 2 diabetes (T2D). VAT from individuals with obesity with euglycemia (n = 11), prediabetes (n = 12) and T2D (n = 6) was harvested during bariatric surgery. VAT bioenergetics and mitochondrial substrate preferences under the influence of pyruvate, glutamine and fatty acids metabolism inhibitors, were assessed using the Seahorse Analyser. VAT expression of OB, GLS1, MPC1, CPT1a, HK2, PDHA1, RPII, β-actin genes was quantified by qRT-PCR. VAT basal mitochondrial respiration was similar across glycaemic groups. In VAT from euglycemic individuals, pyruvate inhibition decreased spare respiratory capacity. In contrast, in VAT from individuals with prediabetes and T2D, ATP-linked respiration increased when glutamine was the sole substrate available, which in individuals with prediabetes, was accompanied by an increase of non-mitochondrial oxygen consumption. There were no differences in the expression of genes related to energy metabolism across groups. These exploratory findings suggest that substrate-dependent VAT respiratory responses may vary across obesity-related glycaemic states despite the absence of detectable basal respiratory differences. The response observed under glutamine-only conditions raises the possibility of compensatory metabolic adaptations in prediabetes, although their mechanisms and potential alteration in T2D remain to be established.
    Keywords:  Bioenergetics; obesity; prediabetes; type 2 diabetes; visceral adipose tissue
    DOI:  https://doi.org/10.1080/21623945.2026.2751414
  24. Molecules. 2026 Oct 29. pii: 3901. [Epub ahead of print]31(21):
      Anticancer treatment alters the secretion and molecular composition of tumor-derived extracellular vesicles (EVs). Chemotherapy, ionizing radiation, and molecularly targeted therapy are associated with changes in EV-associated microRNAs (miRNAs), circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), small nuclear RNAs (snRNAs), proteins, metabolic components, and tumor-associated antigens. Some treatment-associated EV changes are supported by molecular characterization alone, whereas others have been evaluated for functional effects in recipient cells. At the donor-cell level, altered EV release and cargo loading involve RAB family small GTPases, lysosomal degradation, multivesicular body-plasma membrane fusion mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, the exocyst component Exo70, and RNA- and protein-loading processes. In recipient tumor cells, reported responses include changes in WNT/β-catenin and NOTCH signaling, phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), mitogen-activated protein kinase (MAPK), platelet-derived growth factor receptor α (PDGFRα) signaling, glutamine metabolism, and oxidative responses. Evidence supporting individual cargo-response relationships includes both association-based observations and perturbation-based functional validation. In immune cells, C-X-C motif chemokine ligand 1 (CXCL1)-containing EVs increase programmed death-ligand 1 (PD-L1) expression in macrophages, and PD-L1-positive small extracellular vesicles (sEVs) reduce CD8+ T-cell proliferation and granzyme B production, whereas radiation-induced sEVs carrying tumor-associated antigens and heat shock proteins increase antigen presentation and CD4+ and CD8+ T-cell responses. This review separates treatment-associated molecular EV alterations from experimentally evaluated recipient-cell effects to clarify the evidence supporting therapy-induced EV responses.
    Keywords:  EV cargo; anticancer therapy; therapeutic resistance; tumor-derived extracellular vesicles
    DOI:  https://doi.org/10.3390/molecules31213901
  25. Int J Nanomedicine. 2026 ;21 656362
      Polyamine metabolism offers several entry points for cancer nanotherapy, but pathway inhibition, carrier uptake and catalytic cytotoxicity require different evidence. This review examines how nanosystems address compensatory polyamine uptake, normal-tissue exposure and mismatched delivery of combination treatments. We organize the literature by four non-exclusive mechanisms: Deplete reduces a required polyamine pool; Disrupt alters feedback or releases active analogs; Exploit uses experimentally demonstrated transport-associated uptake; and Convert transforms polyamines into reactive products. Representative systems include self-immolative analog carriers, polyamine-decorated particles and enzyme-containing frameworks or local hydrogels. Their reported advantages remain dependent on formulation, administration route and tumor model. We connect material properties to target engagement, adaptive glutamine and arginine metabolism, immune effects and the controls needed to establish a causal nano-enabled benefit. Clinical efficacy of conventional eflornithine in a defined neuroblastoma setting provides pathway validation, whereas the polyamine-directed nanosystems reviewed here remain preclinical. Translation requires exposure-matched comparisons, quantitative tumor-to-normal-tissue pharmacology, repeat-dose recovery and reproducible manufacturing. The framework is intended to guide experimental design and critical comparison, rather than to imply that all platforms share efficacy, selectivity or clinical readiness.
    Keywords:  cancer nanotherapy; clinical translation; enzyme nanocatalysis; metabolic nanoreactor; polyamine metabolism; tumor metabolism
    DOI:  https://doi.org/10.2147/IJN.S656362
  26. PLoS One. 2026 ;21(11): e0361879
      Hepatocellular carcinoma (HCC) is characterized by profound metabolic reprogramming that supports tumor initiation, growth, and metastasis. Understanding how metabolic profiles differ between normal hepatocytes and HCC cells with distinct aggressive phenotypes may help identify metabolic features associated with tumor progression. The Dt81Hepa1-6 cell line, derived from the murine Hepa1-6 hepatoma line, exhibits increased aggressiveness and provides a useful model for investigating metabolic features associated with aggressive behavior. We performed an integrative 1H NMR-based metabolomic analysis of intracellular extracts (endometabolome) and extracellular culture media (exometabolome) from primary hepatocytes, Hepa1-6, and Dt81Hepa1-6 cells collected at 24h and 48h. Multivariate statistical analyses, including PCA and PLS-DA, were used to characterize metabolic differences among the three cell types. Metabolic profiling revealed a clear separation between primary hepatocytes and HCC cells in both endometabolomic and exometabolomic datasets. HCC cells exhibited increased lactate and alanine levels together with decreased intracellular glucose and glutathione, consistent with altered glycolytic and redox metabolism. Time-dependent changes in glucose consumption and lactate release were prominent in extracellular media from both HCC cell lines. The aggressive Dt81Hepa1-6 line displayed a distinct metabolic phenotype characterized by increased extracellular pyroglutamate, citrate, formate and particularly BCAA-derived ketoacids, 2-oxo-isovalerate and 3-methyl-2-oxovalerate. These findings are consistent with alterations in BCAA-associated metabolism, glutamine/glutamate, and TCA-related metabolism in the more aggressive cell line. Overall, the integration of endometabolomic and exometabolomic 1H NMR profiling identifies metabolic features associated with the aggressive phenotype of Dt81Hepa1-6 cells. BCAA-derived ketoacids, pyroglutamate, and TCA-related metabolites emerge as candidate metabolic features that warrant validation in additional experimental and clinical HCC models.
    DOI:  https://doi.org/10.1371/journal.pone.0361879